Harlan Contract Research Services (CRS), a privately held provider of general and specialty toxicology services, and Bertin Pharma, a global solution provider offering R&D outsourcing services headquartered in France, have announced a strategic partnership for early drug development. The companies will offer a wider range of drug discovery and translational medicine services, including expanded profiling and molecule testing, especially in the context of regulatory studies.
Harlan CRS will strengthen its drug discovery and translational medicine offerings utilizing Bertin Pharma’s experience in immunology and biomarkers.
“For Bertin Pharma, this partnership will increase our international visibility and allow us to expand our services by integrating project management capabilities and expertise,” said Xavier Morge, managing director of Bertin Pharma.
“PharmImmune, our joint offer with the French Alternative Energies and Atomic Energy Commission (CEA), is the perfect example of an innovative tool that we will be able to better utilize through our agreement with Harlan CRS,” said Pascal Clayette, head of the immuno-pharmacology department at Bertin Pharma.